Bringing together major UK institutions and specialists in diverse areas of analytical chemistry and human disease research, the on the 25th of January, 2019, the MRC awarded funds to the MAP/UK partnership. It is envisioned that this investment in UK science will create a core capability for delivering high quality metabolic phenotyping data to academics, clinicians and industry to serve the emerging priority area of population phenotyping. Ultimately it is expected that this UK partnership will provide the network, tools and expertise to improve understanding of lifetime disease risks, provide a framework for making collective decisions for future disease and healthcare roadmaps and inform future global public health policies. We anticipate that bringing together the partners and collaborators to define UK metabolic phenotyping practices will significantly advance the UK’s global leadership in the field.